Introduction
Acute promyelocytic leukemia (APL) is genetically characterized by chromosomal translocations that involve the retinoic acid receptor a (RARa) and form RARa fusion genes and proteins (Melnick and Licht, 1999) . RARa is a nuclear receptor for retinoic acid (RA), the natural derivative of Vitamin A (Chambon, 1996) . By forming heterodimers with retinoid X receptors (RXRs), RARa binds to RA response elements (RAREs) on promoters of RA-target genes and recruits protein complexes containing histone deacetylase (HDAC) activities. HDACs induce chromatin remodeling events that render DNA inaccessible to the RNA polymerase II transcription complex and result in transcriptional repression of RA-target genes. Upon RA binding, HDAC activities are released from the RAR-RXR heterodimer and transcriptional coactivators with intrinsic histone acetyltransferase activities (HAT) are recruited to the RAREs. This in turn renders the DNA accessible to the transcriptional machinery and reactivates transcription from RA-target genes (Chambon, 1996; Kouzarides, 1999; Glass and Rosenfeld, 2000) .
The common mechanistic pathways to repress gene transcription involving both histone deacetylation and DNA methylation have been described (Cameron et al., 1999a; Burgers et al., 2002; Jaenisch and Bird, 2003) . Methylation of DNA at CpG dinucleotides is mediated by DNA methyltransferases (DNMT1-3a and -3b) and leads to recruitment of members of the methyl-CpG-binding domain family of proteins (MBDs and MeCPs). DNMT3a and DNMT3b can establish methylation patterns de novo, whereas DNMT1 is responsible for the maintenance of the DNA methylation status during replication. MBDs and MeCPs mediate major chromatin changes and transcriptional silencing preventing the binding of transcription factors to CpG dinucleotides in the gene promoter regions. DNMTs, MBDs and MeCPs can all recruit HDACs and remodel chromatin (Jones et al., 1998; Nan et al., 1998; Ng et al., 1999; Wade et al., 1999; Robertson et al., 2000; Burgers et al., 2002; Jaenisch and Bird, 2003) .
The APL-specific t(15;17) fuses the gene encoding for the RARa located on chromosome 17 to the promyelocytic leukemia (PML) gene on chromosome 15. The resulting PML-RARa fusion product contributes to the block of differentiation of hematopoietic precursors and APL leukemogenesis by disrupting PML function and by silencing the RA signaling pathway through an abnormal recruitment of HDAC and DNMT activities on promoters transcriptionally regulated by RARa, such as RARb2 Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Melnick and Licht, 1999; Di Croce et al., 2002) . RARb2 is an mRNA isoform of RARb gene generated by alternative splicing possessing a canonical RARE on its promoter (bRARE), which is responsible for its RA inducibility (de The`et al., 1990; Chambon, 1996) . At pharmacological doses, RA overcomes this repression and induces the recruitment of transcriptional coactivators, resulting in terminal differentiation of PML-RARa-positive APL blasts in vitro and in vivo Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Melnick and Licht, 1999) .
RA treatment has dramatically changed the prognosis of APL patients and APL represents a unique model for differentiation therapy of human neoplasia (Melnick and Licht, 1999; Lo Coco et al., 2002; Tallman et al., 2002) . However, clinical evidence indicates that RA is per se unable to eradicate the leukemic clone and to cure this disease (Lo Coco et al., 1992 , 1999 Muindi et al., 1992; Miller et al., 1993) . These findings provided a rationale for combinatorial RA þ chemotherapy regimens in the front line of APL treatment, which resulted in both hematological and molecular remission and potential cure in more than 70% of patients (Lo Coco et al., 1999 Tallman et al., 2002) . Unfortunately, the cytotoxic drugs used in APL at doses required for their antileukemic activity in vivo are not devoid of severe side effects. Recent studies indicated the possibility of potentiating or restoring the effect of RA on differentiation by using HDAC inhibitors that targets chromatin remodeling events underlying APL pathogenesis without apparent toxicity in vitro and in vivo Guidez et al., 1998; He et al., 1998 He et al., , 2001 Lin et al., 1998; Warrell et al., 1998) . Moreover, combined treatment of tumor cells with drugs interfering with DNMT and HDAC activities such as azacytidine and trichostatin A (TSA), respectively, results in a more effective reactivation of silenced tumor suppressor genes (Cameron et al., 1999a; Jones and Baylin, 2002; Esteller, 2003) . The link between RA signaling pathways and chromatin structure might provide important targets for the development of novel transcriptional/ differentiation therapy of leukemia, which might induce lasting remissions and spare the shortand long-term toxicity associated with high-dose chemotherapy.
Results

RARb2 promoter and 5
0 portion of exon-1 are methylated in APL blasts
We have recently shown the existence of a minimal region on the first exon of the RARb2 gene that is frequently methylated in APL blasts (seven of nine cases) (Di Croce et al., 2002) . By methylation-specific polymerase chain reaction (MSP), we analysed on the same samples the methylation status of a region of the RARb2 promoter also encompassing the two bRARE and the transcription start site that is aberrantly methylated in a variety of epithelial tumors and tumor-derived cell lines (Coˆte´et al., 1998; Sirchia et al., 2000; Widschwendter et al., 2000; Hayashi et al., 2001) . In Figure 1a are schematically represented the CpG clusters present on a region of about 600 bp on RARb2 promoter/exon-1 and the specific MSP pair of primers used to detect their methylation status (Sirchia et al., 2000; Widschwendter et al., 2000) . By using the P3 primers, a mixture of PCR products corresponding to methylated (M) and unmethylated (U) genomic regions was detectable in all the patient samples (9/9), while only unmethylated forms were amplified in normal CD34 þ hematopoietic precursor cells ( Figure 1b , Table 1 ). Consistent with these findings, RARb2 mRNA transcripts were not detectable in any of these APL samples, while they were detected in CD34 þ normal precursor cells (Table 1) . Interestingly, hypermethylation of these two regions on RARb2 promoter/exon-1 was not associated with the preferential expression of either of the two major APL fusion products (bcr1-or bcr3 PML-RARa) ( Figure 1b , Table 1 ).
RA induces demethylation/re-expression of RARb2 in APL cells containing a functional PML-RARa
We next investigated the biological significance of the effect of RA on RARb2 methylation in APL cells (Di Croce et al., 2002) , by using the APL patientderived NB4 cell line and its RA-resistant subclone NB4-MR4 (Lanotte et al., 1991; Shao et al., 1997) . NB4-MR4 expresses a mutated PML-RARa fusion protein carrying a leucine-proline substitution in the ligand-binding domain. This mutation abrogates the RA-binding capacity of the fusion protein, while it does not affect its ability to bind RAREs and to block transcription from RA-responsive genes (Shao et al., 1997) . RARb2 methylation was measured by the MSP assay, using primers for the 5 0 portion of the exon-1 (P4 primers), the promoter (P3 primers) and a genomic region approximately 300 bp further 5 0 (P1 and P2 primers; Figure 1a) . A partially methylated pattern was detectable on all RARb2 genomic sequences, in both untreated NB4 and NB4-MR4 cells (Figure 1c) . In NB4 cells, RA treatment decreased the annealing of primers for the methylated DNA and induced a progressive accumulation of PCR products corresponding to unmethylated genomic DNA in all the analysed RARb2 genomic sequences that correlated with the re-expression of RARb mRNA transcripts (Figures 1c-2a) . In contrast, RA treatment neither changed the methylation status of RARb2 (Figure 1c and d) nor induced the expression of detectable RARb mRNA transcripts in the NB4-MR4 cells (Figure 2a) . Thus, demethylation and re-expression of RARb2 depend on the activity of a ligand-bound PML-RARa.
RA downregulates the expression of DNA DNMTs in APL blasts DNA methylation is maintained by the activity of DNMTs (Burgers et al., 2002) . To elucidate the mechanisms underlying the effect of RA on the methylation status of the RARb promoter, we investigated the expression levels of different DNMTs (DNMT1, DNMT3a and DNMT3b) in NB4 and NB4-MR4 cells during RA treatment. DNMT mRNA transcripts were present at high levels in untreated NB4 or NB4-MR4 cells (Figure 2 ). In NB4, addition of 1 mM RA induced an early (after 4 h) and marked decrease of DNMT mRNA. After 72 h of RA addition, DNMT1 and DNMT3a mRNA levels were reduced by about 50%, while DNMT3b mRNA levels were nearly undetectable ( Figure 2a) . Notably, no changes in DNMT mRNAs were measurable at any time point during RA treatment of the RA-resistant NB4-MR4 cells (Figure 2a) . Similar results were obtained by measuring the DNMT enzymatic activity of cellular lysates from NB4 and NB4-MR4 cells (Figure 2b ). Indeed, RA treatment reduced the total DNMT enzyme activity of NB4 cells by approximately 40%, while it had almost no effect in NB4-MR4. In NB4 but not in NB4-MR4, downregulation of DNMT expression and activity paralleled the increased expression of RARb and Type II transglutaminase (Type II TGase) transcripts and preceded the RA-induced growth arrest and differentiation occurring after 72 h (Figure 2a , data not shown and Benedetti et al., 1996) . Type II TGase is an endogenous RA target gene whose expression has been found involved in APL cell granulocytic differentiation (Benedetti et al., 1996; Grignani et al., 1998; He et al., 2001) . Interestingly, in NB4 cells, RA reduced the methylation of a region at the start site-exon-1 of the Type II TGase gene by approximately 35% (Figure 1e ). This region is fully demethylated in normal leukocytes (Cacciamani et al., 2002) . DNMT1, DNMT3a and DNMT3b protein levels were also measured by immunoblot analysis using specific antibodies in primary blasts from four newly diagnosed APL patients cultured in the presence or absence of RA. Decreased levels of DNMTs were measurable in all the RA-treated cases (see Figure 3a for representative results of a time-course experiment). Moreover, downregulation of DNMT mRNA expression was detectable by microarray analysis at 4 h in vitro treatment with RA in APL blast from three patients at diagnosis (Meani and Alcalay, submitted). 
Modulation of DNMT expression by RARa-selective agonist and antagonist
To confirm the direct involvement of the RARa signaling pathway in the modulation of DNMT expression, NB4 cells were treated with the RARa-selective retinoid AM580, in the absence or in the presence of the RARa-selective antagonist Ro 41-5253 (Apfel et al., 1992; Martin et al., 1992) . Increasing concentrations of the RARa antagonist Ro 41-5253 (0.5-2 mM) inhibited the effect of the RARa-selective retinoid AM580 on DNMT1, DNMT3a and DNMT3b expression and prevented the induction of RARb mRNA ( Figure 2c ). These results confirm that expression of DNMTs is regulated through the binding of RA to an RARa ligand-binding domain.
To investigate whether the effect of RA on DNMTs expression is direct, NB4 cells were treated with the protein synthesis inhibitor cycloheximide (25 mg/ml). Cycloheximide treatment did not prevent the RA induction of RARb transcripts, which is consistent with its transcriptional regulation by RA. However, in the presence of cycloheximide, DNMT1 and DNMT3a expression were minimally affected by RA treatment, while DNMT3b transcripts were reduced by more than 60% (Figure 2d ). Therefore, it appears that DNMT1 and DNMT3a downregulation requires de novo protein synthesis, while downregulation of DNMT3b expression is -at least in part -transcriptionally downregulated by RA directly.
Downregulation of DNMT expression and RARb2 demethylation/re-expression during differentiation therapy of APL
We then investigated the methylation status of RARb2 gene and the expression levels of DNMTs and RARb2 in peripheral blood cells from a consenting APL patient treated with RA (GIMEMA-AIDA 0493 protocol: simultaneous administration of 45 mg/m 2 /day oral RA, every day and intravenous Idarubicin 12 mg/m 2 at days 2, 4, 6 and 8) (Mandelli et al., 1997) . Prior to treatment, analysis of peripheral blood blasts revealed the previously described patterns of RARb promoter methylation (Figure 3b ), RARb2 gene silencing and high levels of DNMTs expression (Figure 3c ). At 24 h after the first dose of RA, when chemotherapy had not yet started, the RARb2 promoter region was partially demethylated, DNMT1 and DNMT3a mRNA levels were reduced by about 50%, DNMT3b mRNA levels were nearly undetectable and RARb2 mRNA re-expression was seen ( Figure 3 ). After 96 h of combined treatment, the RARb2 promoter region was completely unmethylated and RARb gene highly expressed. Moreover, a time-dependent increase of Type II TGase mRNA transcripts was also measurable in the APL patient blasts (Figure 3d ).
Consistent with a specific role for the DNMTs in these events, the mRNA expression of a methyl-CpG-binding protein (MBD2/dMTase), proposed also to function as a demethylase (Bhattacharya et al., 1999) , was not affected by RA treatment in APL blasts (Figure 3b) .
Thus, downregulation of DNMTs expression and demethylation/re-expression of RARb gene are early events induced by in vivo treatment with RA, related to APL blast differentiation.
RA decreased the occupancy of DNA-DNMT at RARb2-target promoter/exon-1
We next determined whether the effect of RA on RARb2 gene induction is mediated through the release of DNMT1, DNMT3a, DNMT3b and HDAC1 recruited by PML-RARa at the bRARE site of RARb2 promoter Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Di Croce et al., 2002) . Chromatin fragments were prepared from NB4 and NB4-MR4 cells treated or not with RA for 24 h, immunoprecipitated with antibodies specific for RARa, PML, DNMT1, DNMT3a, DNMT3b or HDAC1 and amplified by PCR using primers recognizing a region surrounding the bRARE and exon-1 of the endogenous RARb2 gene. Chromatin immunoprecipitation (ChiP) patterns from untreated NB4 and NB4-MR4 cells revealed that DNMT1, DNMT3a, DNMT3b and HDAC1 were all present with PML-RARa on these regions of RARb2 (Figure 4) . In NB4 but not in NB4-MR4 cells, 24 h of RA treatment decreased the levels of PML-RARa at the RARb2 promoter and slightly increased the binding of the endogenous RARa as detected by using anti-RARaand anti-PML-specific antibodies (Figure 4a ). These findings are in agreement with the fact that in RA- Figure 1a .
A sample representing 0.02% of total chromatin (input) was included in the PCR analysis. The amplification of a GAPDH coding region was performed to detect nonrelevant cellular DNA sequences
Epigenetic events in APL blasts differentiation F Fazi et al responsive APL, RA-induced PML-RARa degradation through the activation of caspases and the proteasome but increased the expression of wild-type RARa (Chomienne et al., 1991; Nervi et al., 1998; Fanelli et al., 1999) . Notably, RA treatment strongly reduced (but did not abolish) the interaction of DNMT1, DNMT3a, DNMT3b and HDAC1 at these chromatin regions surrounding the bRARE site and exon-1 of the RARb2 gene in NB4 cells, while it did not affect their binding at the same promoter site in NB4-MR4 cells, thus indicating that these events are restricted to RAsensitive APL blasts (Figure 4b ).
Inhibition of HDAC and DNMT activities increases RA-induced expression of endogenous RA-target genes and APL blast differentiation
Therefore, we investigated the effects of drugs interfering with HDAC or DNMT activities (TSA or 5-azacytidine, respectively) on RA-target promoters, endogenous RA-target genes and differentiation in NB4, NB4-MR4 cell lines and primary blasts from APL patients. Initially, we investigated the effect of these compounds on transcription of the endogenous RARb gene. Quantitative RT-PCR (qRT-PCR) showed that TSA and 5-azacytidine, as single agents, did not affect RARb expression, while they potentiated the effect of RA on this gene expression (Figure 5a ). Again, RA/TSA/ 5-azacytidine appeared as the most potent combination in reactivating RARb expression in either RA-responsive or RA-resistant APL blasts.
Interestingly, RA/TSA/5-azacytidine had comparable effects on the endogenous RA-target gene Type II TGase, as measured by qRT-PCR or by directly assaying its enzymatic activity, with the slight difference that 5-azacytidine was consistently more potent than TSA in increasing the effect of RA (Figure 6a and b) .
Next, we analysed myeloid differentiation induced by RA, TSA and 5-azacytidine, as single agents or in combination, in NB4 cells (not shown), NB4-MR4 and in primary APL patient blasts using morphological criteria (not shown), the NBT dye reduction assay and direct immunofluorescence analysis of CD11b, a myeloid-specific cell surface antigen (Figure 5b ). Myeloid differentiation-associated parameters were poorly modified by TSA or 5-azacytidine as single agents. However, TSA or 5-azacytidine potentiated the effect of RA on NB4 and primary APL blast differentiation, which was further increased by TSA þ 5-azacytidine in combination. In NB4-MR4 cells, 5-azacytidine in combination with RA, with or without TSA, most potently restored RA-induced differentiation, as evaluated by NBT assay.
Effect of RA, HDAC and DNMT inhibitors on the chromatin status at the RARE region of RARb2 promoter in RA-sensitive and RA-resistant APL blasts
The effects of TSA and 5-azacytidine on DNA methylation at the RARE site of RARb2 in NB4, NB4-MR4 and in primary blasts from an APL patient (APL #12) were measured by MSP using the P3 primers (Figure 1a and 7a) . RA treatment of 24 h decreased by about 50% the methylation levels of this region in NB4 and APL blasts but not in RA-resistant NB4-MR4. TSA did not significantly affect the methylation status of this RARb genomic region nor did it increase the effect of RA. 5-azacytidine decreased the methylation levels at this RARb2 site. Interestingly, in APL blasts, the demethylating activity of 5-azacytidine was potentiated by treatment with either RA or TSA as revealed by the marked decrease of the methylated P3 products (Figure 7a) .
We then analysed the levels of histone acetylation on the same region of the RARb2 promoter encompassing the bRARE by ChiP, using anti-acetylated H4 antibody and PCR amplification (Figure 7b ). RA treatment increased H4 acetylation of this region in NB4 but not in NB4-MR4 cells, whereas TSA increased H4 acetylation in both these cell lines. Histone H4 acetylation by TSA was slightly increased by combined treatment with RA in NB4 but not in NB4-MR4. The addition of 5-azacytidine as single agent or in combination with RA did not significantly modify the acetylation status of histone H4 at these sites on RARb in either NB4 or (Figure 5b ). This is consistent with the fact that RARb is a target gene of RARa, which is required to activate its expression (Chambon, 1996) . Thus, both TSA and 5-azacytidine induced chromatin changes that positively affect RA modulation of target gene transcription in either RA-responsive or RA-resistant APL.
Discussion
Abnormal recruitment of HDAC and DNMT activities at the promoters of RA-target genes, such as RARb2, is critical to the leukemogenetic activity of the APLassociated PML-RARa fusion product Guidez et al., 1998; He et al., 1998; Lin et al., 1998; Di Croce et al., 2002) . RARb2 is considered a tumor suppressor gene that, in a variety of human malignancies (e.g. lung, breast, colon and gastric tumors), is silenced by DNA methylation at promoter CpG clusters (including the bRARE and the transcriptional start site) (Coˆte´et al., 1998; Momparler and Bovenzi, 2000; Sirchia et al., 2000; Widschwendter et al., 2000; Hayashi et al., 2001) . In APL blasts and cell lines, RARb is not expressed and its promoter region was found hypermethylated within a region including the 5 0 portion of the exon-1 (Di Croce et al., 2002) . Here, we show that the CpG clusters surrounding the two RARE and the TATA box are also aberrantly methylated in APL blasts, thereby providing an additional mechanistic link between methylation and transcriptional silencing of RARb in APLs. The presence of a CpG cluster on the 5 0 portion of the exon-1 genomic region at approximately one nucleosome distance from the two bRARE elements suggests a more close vicinity of these regions in cells. Thus, the possibility of a methylation of this CpG cluster by the multiprotein complex containing DNMT activities formed by PML-RARa at its target sites.
In addition, the degree of methylation/unmethylation at different CpG clusters appeared highly variable within each case. Since this was found in blasts from APL patients presenting X75% leukemic infiltration and in APL cell lines, it might result from an allelic heterogeneity of RARb2 methylation within cells rather than to a mixed cell population. Interestingly, a heterogeneity of the methylation patterns seems to be a functional determinant of the expression patterns in primary and cultured tumors. Heterogeneous methylated alleles and transcriptional silencing have also been described for other tumor suppressor genes, such as p15 in leukemias and Rb in sporadic retinoblastomas (Stirzaker et al., 1997; Cameron et al., 1999b) . Figure 7 Effect of RA, TSA and 5-azacytidine as single agents or in combination on the chromatin status at RARb2 promoter/exon-1 region in APL blasts. NB4, NB4-MR4 cells and primary blasts from an APL case (#12 , Table 1 ) were treated or not for 48 h with 1 mM 5-azacytidine (Aza) prior to the addition of TSA (100 ng/ml) and/or RA (1 mM) as single agents or in combination for 24 h as indicated in the figure. (a) MSP: using the P3 primer to detect specifically the methylation status at the RARE and exon-1 regions of RARb2 gene; (b) ChIP: NB4 and NB4-MR4 cell lines were treated with 1 mM 5-azacytidine for 48 h before the 1 h addition of 1 mM RA, 100 ng/ml TSA alone or in combination as indicated. Chromatin was immunoprecipitated with an a-acetyl histone H4 antibody (H4-Ac) or no antibody (no-Ab) and analysed by PCR as described in the legend of Figure 4 and in the Materials and methods section. A sample representing 0.02% of total input chromatin (input) was included in the PCR analysis. Nonrelevant cellular DNA sequences were detected by the amplification of a GAPDH coding region Figure 6 Inhibition of HDAC and/or DNMT activities potentiates RA induction of Type II TGase and terminal differentiation of primary APL blasts: (a) NB4, NB4-MR4 cells and primary blasts from an APL case (#12 , Table 1 ) were treated with 5-azacytidine (Aza 1 mM) for 48 h before TSA (100 ng/ml) and/or RA (1 mM) addition. qRT-PCR was performed after 24 h of treatment as described in the Materials and methods section. (b) Induction of Type II TGase activity in NB4 and NB4-MR4 cells and in fresh blasts from a representative APL case (# 7, Table 1 ). Cells were treated with 5-azacytidine (Aza) for 48 h and then TSA and/or RA were added for additional 4 days as indicated. Type II TGase activity was assayed as described (Benedetti et al., 1996) Epigenetic events in APL blasts differentiation F Fazi et al
With respect to the mechanisms leading to CpG methylation in cancer, evidence is accumulating that tumor suppressor genes are silenced by de novo methylation of their promoter regions (Burgers et al., 2002; Esteller, 2003) . Interestingly, DNMT1, DNMT3a and DNMT3b expression has been found upregulated in AML blasts, as compared to normal CD34 þ bone marrow progenitors (Melki et al., 1998; Mizuno et al., 2001) . Here, we show that treatment with RA, which reprograms APL blasts to a nonleukemic phenotype, reduced DNMT expression and activity. More specifically, RA treatment induced an early and coordinated decrease of DNMT1, DNMT3a and DNMT3b expression/activity, which correlated with demethylation of the promoter/exon-1 regions of its target gene RARb2 in RA-responsive APL blasts cultured in vitro, and in blood samples from one APL patient undergoing treatment with RA and chemotherapy. Of note: (i) DNMT3b mRNA expression, which shows the earliest and largest decrease during normal myeloid differentiation (Mizuno et al., 2001) , was mainly affected by RA treatment in the RA-responsive APL blasts in vitro and in vivo; (ii) downregulation of DNMT expression/ activity, of their occupancy at RARE sites and exon-1 on RARb2 gene and of the methylation status of RARb2 promoter/exon-1 are not measurable in the RA-resistant NB4-MR4 cells following RA treatment; (iii) nanomolar concentrations of a selective RARa agonist (AM580) also modulated DNMT expression, and its effect is fully abolished by an RARa-selective antagonist (Ro41-5253). Together, these results suggest a direct involvement of RA binding to either a functional PML-RARa or endogenous wild-type RARa in the downregulation of DNMT expression in APL. Indeed, a decreased expression of DNMT1, DNMT3a and DNMT3b and granulocytic differentiation were also induced by the RARa agonist AM580 in HL-60 cells (data not shown). HL-60 is a myeloid leukemia cell line morphologically and biochemically very similar to the APL blast but lacks the t(15;17) and express a functional RARa (Collins et al., 1990) . This raises the possibility that downregulation of DNMT expression could be a more general mechanism of RA action in cells, which in myeloid leukemia blasts relates to its action on myeloid differentiation. Accordingly in APL blasts, RA treatment decreased the methylation status at specific sites on Type II TGase, which is a recognized RA target gene involved in granulocytic differentiation of APL blasts (Benedetti et al., 1996; Grignani et al., 1998; He et al., 2001) .
The expression levels of DNMT1 and DNMT3a remained unchanged after RA treatment in the presence of the protein synthesis inhibitor cycloheximide, while the RA-induced downregulation of DNMT3b appeared only partially affected. Thus, other pathways inducing de novo protein synthesis are necessary for the modulation of DNMT1 and DNMT3a transcription by RA, while DNMT3b levels appear to be, at least in part, transcriptionally downregulated by RA. Interestingly, a search performed using the MatInspector Professional software indicated the presence of a putative RARE site (agcgaggTCAAagtcacca) at about À1200 bp relative to the transcription start site on the DNMT3b gene (Genebank: NM006892 and AL035071), while putative RARE sites were not found on the DNMT1 and DNMT3a genomic sequences (Meani and Alcalay, submitted).
The reversion of both DNA methylation and histone deacetylation status imposed by PML-RARa at RAtarget promoters may represent a key step for RA to trigger terminal differentiation of malignant cells and induction of disease remission in APL patients. Indeed, we found that 5-azacytidine and TSA were both active in potentiating the effect of RA on endogenous RA target genes (RARb and Type II TGase) and myeloid differentiation in either RA-responsive or RA-resistant APL blasts. Note that in NB4-MR4, 5-azacytidine is consistently more potent than TSA in restoring RA response, suggesting that aberrant DNMT activity plays a major role in the development of RA resistance of APL blasts. Interestingly, by MSP assay we found that 5-azacytidine caused an extensive demethylation at RARb2 that is increased by either RA or HDAC inhibition in both RA-responsive and RA-resistant APLs. These chromatin changes are consistent with the functional potentiation of RA action on endogenous RA-target genes expression (RARb and Type II TGase) and myeloid differentiation of these blasts. Indeed, TSA potentiates or restores the effect of RA on the expression of RARb2 without changing the methylation status at the endogenous promoter, while ChIP analyses showed that 5-azacytidine does not modify the acetylation levels of histone H4 at RARb2 sites.
Epigenetic agents that target DNMT and HDAC activity may have a more wide application in leukemia treatment, since chromatin remodeling events resulting in silencing of RA signaling pathways are not restricted to APL but may also characterize other AMLs regardless of their underlying genetic alteration (Ferrara et al., 2001; Gottlicher et al., 2001; Petti et al., 2002) . Functional RA-responsive elements are present in the promoter region of transcription factors involved in granulocytic myelopoiesis (Tenen et al., 1997) , suggesting that a regulated expression of RA-responsive genes may be crucial for effective myeloid differentiation and that common pathways of leukemogenesis could lie along the control of specific chromatin structures in terms of transcriptional activation or repression. Thus, targeting of specific chromatin remodeling activities may represent a therapeutic strategy potentially applicable also to RA-resistant APL patients and to AML in which an aberrant transcriptional repression underlies gene silencing, maturation arrest and leukemogenesis.
Materials and methods
Reagents and antibodies
All-trans-RA and 5-azacytidine were from Sigma. TSA was from WAKO Chemicals. The RARa-selective retinoid AM580 (Ro 40-6055) (Martin et al., 1992) and the RARa antagonist Ro41-5253 (Apfel et al., 1992) were kindly provided by Dr Klaus, Hoffmann La Roche, Basel, Switzerland. Antibodies were purchased from New England Biolabs (a-DNMT1), Abcam (a-DNMT3a, a-DNMT3b), Upstate Biotechnology (a-acetyl histone H4) and SantaCruz (a-HDAC1; a-RARa; a-PML).
Clinical samples
Leukemic blasts from bone marrow and/or peripheral blood were obtained after informed consent from 15 newly diagnosed APL patients showing X75% leukemic infiltration. Blasts isolation and molecular characterization of the APL-associated PML-RARa isoforms (bcr1, bcr2 and bcr3) were performed as described (Lo Coco et al., 1992) . CD34 þ cells were isolated from the bone marrow of informed normal donors by Ficoll-Hypaque density-gradient centrifugation, depletion of adherent cells by adherence to plastic and purification by immunomagnetic separation (Miltenyi, Biotech) as recommended by the manufacturer. Flow cytometric analysis confirmed that more than 90% of the cells were CD34 þ .
Cell cultures
APL patient blasts, the RA-responsive APL cell line NB4 (Lanotte et al., 1991) and the RA-resistant APL cell line NB4-MR4 (Shao et al., 1997) were maintained in RPMI 1640 medium and 10% fetal calf serum as described (Benedetti et al., 1996; Ferrara et al., 2001) . APL blasts were treated with 5-azacytidine (1 mM) 48 h prior to the addition of the HDAC inhibitor TSA (100 ng/ml). RA (1 mM) was added 1 h after the addition of TSA treatment. Cell proliferation and differentiation was evaluated and quantified as described (Benedetti et al., 1996; Ferrara et al., 2001) .
Bisulfite genomic sequencing and MSP assays
Bisulfite genomic sequencing and MSP assays were performed on bisulfite-treated genomic DNA to detect the methylated status on a region of about 600 bp of RARb2 promoter/exon-1 or on a region of about 250 bp at the promoter/exon-1 of Type II TGase as reported previously (Herman et al., 1996; Sirchia et al., 2000; Widschwendter et al., 2000; Cacciamani et al., 2002; Di Croce et al., 2002) .
RNA preparation and analysis
Total RNA was isolated by the guanidine thiocyanate-CsCl procedure or the TRIzol Reagent (Invitrogen). Northern blot analysis was performed using 30 mg total RNA as described previously (Benedetti et al., 1996) . The RARb probe was the 1.4 kb PstI-XhoI restriction fragment of the plasmid pCOD20 (de The`et al., 1990) , kindly provided by Dr de The`(Paris, France). The Type II TGase probe was the 3.3 kb EcoRI restriction fragment of the pTG3400, kindly provided by Dr Davies (University of Texas, Houston, TX, USA) (Benedetti et al., 1996) . The GAPDH 1.1 kb PstI cDNA restriction fragment of the chicken glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Dugaicyzk et al., 1983 ) was used to normalize the level of gene expression. DNMT1, DNMT3a and DNMT3b cDNA probes were generated by RT-PCR performed in the HL60 cell line using specific primers as described (Mizuno et al., 2001) . The cDNA probes were labeled with [a-32 P]deoxycytidine triphosphate (3000Ci/mmol; Amersham Pharmacia Biotech). The expression of RARb, DNMT1, DNMT3a, DNMT3b, methylated DNA-binding protein 2/DNA demethylase (MBD2/dMTase) and GAPDH were analysed on total RNA by semiquantitative RT-PCR as described (Bhattacharya et al., 1999; Ferrara et al., 2001; Mizuno et al., 2001) or by qRT-PCR performed on a ABI PRISM 7000 Sequence Detection System (Applied Biosystem). qRT-PCR of RARb2 gene was performed as described (Sirchia et al., 2002) . Taqman oligonucleotides (Assay on Demand) for Type II TGase and GAPDH were purchased from Applied Biosystem and used as recommended by the manufacturer. All reactions were performed in triplicate. Delta-delta Ct values were normalized with those obtained from the amplification of a GAPDH. The results are expressed as fold induction relative to untreated cells on an arbitrary scale where uninduced value is set to 1.
Immunoblot analysis
Total cell extracts (50 mg of proteins) were fractionated on 10% SDS-polyacrylamide gel, electroblotted to nitrocellulose membrane (Protran, S&S) and immunoblotted using anti-DNMT1 (1 : 1000), anti-DNMT3a (1 : 250) and DNMT3b (1 : 250) antibodies. Immunoreactivity was determined using the ECL method (Amersham).
ChiP assay
Proteins from 2 Â 10 6 cells were crosslinked to DNA by direct addition to the culture medium of formaldehyde at 1% final concentration for 10 min at 371C. After sonication, chromatin was immunoprecipitated overnight with 5-8 ml of the indicated antibodies. A genomic region of about 230 bp containing the two bRARE sites and the 5 0 portion of exon-1 on the RARb2 gene (À112 bp to þ 119 bp) was amplified by PCR using the primers (sense 5 0 -TCC TGG GAG TTG GTG ATG TCA G-3 0 and antisense 5 0 -AAA CCC TGC TCG GAT CGC TC-3 0 ) and conditions as described previously (Coˆte´et al., 2002) . Nonrelevant cellular DNA sequences were detected by the amplification of a GAPDH coding region as described (Sirchia et al., 2002) .
Endogenous DNMT activity assay
Endogenous DNMT activity assay was measured on nuclei isolated from 20 Â 10 6 cells. Cells were suspended in ice-cold 10 mM Tris-HCl (pH 7.8), 4 mM MgCl 2 , 1 mM EDTA, 0.5 mM DTT, 1% Triton X-100, 0.25 M sucrose. After 15 min on ice, nuclei were collected by centrifugation, washed and suspended in 10 mM Tris-HCl (pH 7.8), 0.35 M NaCl, 1 mM EDTA, 0.5 mM DTT and 0.2 mM PMSF. Chromatin was eliminated by centrifugation at 18 000 r.p.m. for 20 min. Cell extracts were diluted with 200 ml of the extraction buffer without NaCl. Methyltransferase activity was measured on 30 ml of diluted extract (5-10 mg protein), in a final volume of 80 ml in the presence of 5 mM S-adenosyl-L-[methyl-3 H]methionine (20 mCi/ml, NEN Life Science Products), 20 mg/ml poly(dIdC) Á poly(dI-dC) and incubated for 2 h at 371C. Tests were processed as described previously (Carotti et al., 1989) . Each determination was performed in triplicate.
TGase activity assays
TGase activity assays were performed on total homogenate as previously described by measuring the incorporation of [ 3 H]putrescine (12.6 Ci/mmol; Amersham Corp.) into casein in duplicate or triplicate cultures (Benedetti et al., 1996) . Blasts were pretreated for 48 h in culture with the DNMTs inhibitor 5-azacytidine before the addition of TSA and/or RA and assayed for TGase II activity after 4 days.
